PMC:7335697 / 30351-30593 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T86","span":{"begin":46,"end":51},"obj":"Body_part"}],"attributes":[{"id":"A86","pred":"fma_id","subj":"T86","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"One of the key questions in the management of liver transplant patients affected with COVID-19 concerns the management of the immunosuppression.33 In our cohort, the immunosuppression was reduced in 39% of the patients and discontinued in 7%."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T64","span":{"begin":46,"end":51},"obj":"Body_part"}],"attributes":[{"id":"A64","pred":"uberon_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"One of the key questions in the management of liver transplant patients affected with COVID-19 concerns the management of the immunosuppression.33 In our cohort, the immunosuppression was reduced in 39% of the patients and discontinued in 7%."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T234","span":{"begin":86,"end":94},"obj":"Disease"}],"attributes":[{"id":"A234","pred":"mondo_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"One of the key questions in the management of liver transplant patients affected with COVID-19 concerns the management of the immunosuppression.33 In our cohort, the immunosuppression was reduced in 39% of the patients and discontinued in 7%."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T354","span":{"begin":46,"end":51},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T355","span":{"begin":46,"end":51},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":"One of the key questions in the management of liver transplant patients affected with COVID-19 concerns the management of the immunosuppression.33 In our cohort, the immunosuppression was reduced in 39% of the patients and discontinued in 7%."}

{"project":"LitCovid-PubTator","denotations":[{"id":"806","span":{"begin":63,"end":71},"obj":"Species"},{"id":"807","span":{"begin":210,"end":218},"obj":"Species"},{"id":"814","span":{"begin":86,"end":94},"obj":"Disease"}],"attributes":[{"id":"A806","pred":"tao:has_database_id","subj":"806","obj":"Tax:9606"},{"id":"A807","pred":"tao:has_database_id","subj":"807","obj":"Tax:9606"},{"id":"A814","pred":"tao:has_database_id","subj":"814","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"One of the key questions in the management of liver transplant patients affected with COVID-19 concerns the management of the immunosuppression.33 In our cohort, the immunosuppression was reduced in 39% of the patients and discontinued in 7%."}

{"project":"LitCovid-sentences","denotations":[{"id":"T354","span":{"begin":0,"end":242},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"One of the key questions in the management of liver transplant patients affected with COVID-19 concerns the management of the immunosuppression.33 In our cohort, the immunosuppression was reduced in 39% of the patients and discontinued in 7%."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T222","span":{"begin":46,"end":51},"obj":"UBERON:0002107"},{"id":"T223","span":{"begin":86,"end":94},"obj":"SP_7"},{"id":"T224","span":{"begin":126,"end":143},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T225","span":{"begin":166,"end":183},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T2882","span":{"begin":46,"end":51},"obj":"UBERON:0002107"},{"id":"T19017","span":{"begin":86,"end":94},"obj":"SP_7"},{"id":"T69160","span":{"begin":126,"end":143},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T92426","span":{"begin":166,"end":183},"obj":"CHEBI:35705;CHEBI:35705"}],"text":"One of the key questions in the management of liver transplant patients affected with COVID-19 concerns the management of the immunosuppression.33 In our cohort, the immunosuppression was reduced in 39% of the patients and discontinued in 7%."}